Companion Diagnostics (CDx) Stratified Precision Care New Market / Commercial Development VP @ CDx Precision Care Strategic Roadmapping + Risk/Reward Economic Valuations & Decision Analysis
Corporate Strategy & Business Development + Bioscience Innovation to Commercialization Coach/Mentor @ Certified Licensing Professional (CLP); Life Science Licensing & Biotech Business Development Leader
PhD, Chemical & Biomolecular Engineering, College of Chemistry @
University of California, Berkeley
✉ [email protected]
► BIOTECHNOLOGY BUSINESS BACKGROUND
As a corporate development leader, I’m dedicated to building bioscience businesses that will meaningfully improve the quality of people’s lives & have significant fiscal impact. By focusing on molecular diagnostics & drug discovery tools Innovation to Commercialization (I2C), I’ve scouted & evaluated early-stage genomics technology licensing, commercial alliance &
✉ [email protected]
► BIOTECHNOLOGY BUSINESS BACKGROUND
As a corporate development leader, I’m dedicated to building bioscience businesses that will meaningfully improve the quality of people’s lives & have significant fiscal impact. By focusing on molecular diagnostics & drug discovery tools Innovation to Commercialization (I2C), I’ve scouted & evaluated early-stage genomics technology licensing, commercial alliance & market opportunities. Applying a valuation-powered approach to deal & decision making has yielded much I2C success. Seeking to leverage my intellectual property strategy & business development accomplishments, I'm committed to championing new Bio•I2C product planning & partnering.
►► CURRENT PRECISION HEALTH CARE EXPERIENCE
By investigating the pharmaco-economics of genome guided treatments, I help level the fiscal playing field for personalized healthcare providers, including pharmaceutical, IVD & biotech companies. I’m spearheading financial forecasting & risk analysis of biomarker based companion diagnostics (CDx) stratified immuno-oncology targeted therapies (w/ the Gx, Dx, Rx confluence represented visually by a triple helix^). I’ve showcased my achievements catalyzing converging Bio•I2C by giving 25-invited talks, including in Guangzhou, PRC & @ the Mayo Clinic's Individualizing Medicine conference.
►►► LIFE SCIENCE COMMERCIALIZATION BUSINESS DEVELOPMENT EXPERTISE
While advancing 4 biotools commercial units, my tech assessment, roadmapping & biz dev activities contributed to the launch of 9 pre-clinical Rx screening & Dx products + a Silicon Valley venture’s $189 MM IPO. Having excelled in I2C prospecting + partnering as a Certified Licensing Pro, I’ve sourced 100’s of emerging opportunities + structured, negotiated & closed 65 omic, Dx or Rx collaborative deals + 3 M&A transactions valued @ $280 MM. Stemming from my consultative strategic solution sales success, I've appraised 7 Bio•I2C initiatives @ $1.7 billion APV.
Companion Diagnostics (CDx) Stratified Precision Care New Market / Commercial Development VP @ By characterizing the pharmaco-economics of precision (or personalized) healthcare using biomarker enabled companion diagnostics (CDx) as Real Options within a decision-tree analysis framework, I am determining the financial value added by the CDx molecular test within the stratified medicine system. Please also see www.CDxPrecisionHealth.com for more information regarding the consultancy's capabilities directed toward catalyzing precision care•I2C.
►►► For the representative oncological cases investigated, the risk-adjusted expected Net Present Value (eNPV) of my financial model predictions is in excess of $250 Million. ◄◄◄
The results of these economic studies are being used to help level the playing field among key stakeholders, including diagnostic biotool testing & targeted treatment healthcare-providers + payers.
On behalf of CDx Precision Healthcare, I was invited & spoke at a Molecular Medicine & Diagnostics Conference in China ('12) as well as presented at an American Chemical Society (ACS) meeting ('13) & at the Mayo Clinic's Individualizing Medicine Conference ('13). Please see additional info regarding these presentations provided below in the Publications section of my LI profile, the LI Company Page & the Consultancy's webpage with the URL of http://www.CDxPrecisionHealth.com.
Also please see my illustrations, charts & figures - shown below - summarizing the CDx/t•Rx landscape, its market size & growth forecasts. If you'd like additional info about my contributions to the genomics powered precision care field, including targeted therapies for oncological immune disorders + other disease indications, feel free to inquire. My contact coordinates are provided within. From July 2011 to Present (4 years 4 months) United StatesCorporate Strategy & Business Development + Bioscience Innovation to Commercialization Coach/Mentor @ With a goal of disseminating & advancing Strategic Business Development (SBD) & licensing information & understanding among the extended network of fellow CLP leaders, other Licensing Executives Society (LES) colleagues as well as neophytes & students (please see the schematics - below - for highlights of my career SBD experience), we are collectively committed to promoting & encouraging intrapreneurial collaborative interaction & sharing among our group members pertaining generally to:
Emerging Biotechnological Innovation to Commercialization (Biotech•I2C), new venture creation, funding & financial valuations (for info regarding my specific Bio•I2C projects, please see summary below),
Lean bio-business building & product roadmapping (info on my strategic planning activities is available in the Bio-Com/Moto Life Sciences (MLS) eSensor & CodeLink Work-Exp. & Projects sections below),
Value-added contribution of genomics driven companion diagnostics (CDx) testing biotools in the stratified-medicine ecosystem (see above-referenced slidedocs)
Attending workshops & conferences (partial list provided -below- of meetings in which I presented),
Researching disruptive biotechnologies/ventures, tracking trends & joining in univ/industry discussions.
Additional related Biotech•I2C information can also be found at my personal webpage with the URL of http://www.AlanKHauser.com. From 2008 to Present (7 years) United StatesNew Business Development, Strategic Marketing, Technology Licensing & Commercialization Director @ »»» As the Technology Licensing & Business Development Executive Director of Northwestern's Innovation & New Ventures Office (INVO) from Feb. 2010 to June 2011, I was dedicated to:
Directing NU's tech licensing team of 5 full-time scientific/engineering staff, each with an advanced graduate degree, plus > 40 entrepreneurs in residence (EIR interns) that conducted the following:
✔ Responsible for tech transfer team's evaluation of approx 200 invention disclosures per year & commercially assessed > 50 I2C opps in partnership with the executive & student/postdoc EIR interns;
✔ Oversaw 30 executed & 20 pending new license agreements in my last academic year 2010-2011
& cumulatively more than 20 transactions/opps directed toward diagnostics (Dx) testing tools for IVD companies or therapeutics (Rx) for pharmaceutical & biopharma corporations (see schematic -below rt)
✔ Managed, marketed & licensed proprietary portfolios of Rx candidates + Dx content & biotools to treat + test for various disease indications, including cancers, blood-related disorders & immune deficiencies.
»»» As a Certified Licensing Professional & the Business Development Director of Northwestern's Technology Transfer Program (TTP) from Feb. 2008 to Feb. 2010, I was committed to:
Bridging the gap between NU research & its practical use for public benefit resulting in the following:
✔ Marketing more than 150 NU embryonic/emerging technologies & patent portfolios led to my structuring & negotiating 20 consummated license & option agreements;
✔ Licensing revenue from 2008 to 2011 was in excess of $150 million per year for my 3 1/2 years (a case study has been prepared by the Kellogg business school highlighting this NU Rx out-licensing deal).
✔ Assisted in building & nurturing the culture of innovation to commercialization (I2C), including NU spinouts, which raised $199 million in venture/corporate investment in the academic year 2010-2011. From February 2008 to June 2011 (3 years 5 months) Evanston and Chicago, ILStrategic Roadmap Planning, Market Research, IP Landscaping, Valuation & Commercial Development Exec @ Bio-Com International is a life sciences management consultancy providing specialized I2C advisory services to enhance & sustain the competitive advantage of its clients. At the confluence of its 3 core competencies (BUSINESS, IP & BIOSCIENCE), econometric valuation tools are a key differentiator & central to the firm’s risk/reward decision-analysis & strategy-development practice areas. See www.biocom.us
Having built & deployed the Bio•Biz Builder strategic commercial roadmapping & financial forecasting frameworks (see slide below right), including Rx economic analysis using probability-weighted capitalized & discounted cost models for pharma/biotech drug discovery & clinical dev, I completed the following:
► Developed strategic plans for high-impact market expansion opportunities based on forward-looking intelligence & economic analytics, including valuing 4 genomics enabled bioscience innovation to commercialization (Bio•I2C) initiatives @ $1.5 Billion.
► Evaluated emerging biotechnologies, including building 12 strategic product/IP competitive roadmaps for visualizing 7 clients’ Bio•I2C landscapes.
Assessed & determined value of new bioprocesses, products, licensing opps & ventures (see docs below); representative client projects include:
■ RNA interference (RNAi) for research & drug screening w/ an ROI of 36% IRR & 22x Cash on Cash that when realized will quadruple the public company's annual gross profit
■ Active pharmaceutical ingredients (API) micronization for drug delivery/dev resulting in a $425 M risk-adj eNPV licensing opp (see PPT pres below)
■ Automated next generation sequencing (NGS) system yielding 32% IRR & 16x CoC ROI metrics
■ Proprietary formulations for addressing unmet needs in reproductive health & fertility ($2 B mkt opp)
■ As interim CEO of startup developing proprietary OTC products, created value yielding ROI profitability for a 7 year exit of 107% IRR, 160 CoC & $990 M valuation that led to 1st B2B mfg & mktg partnership. From August 2004 to February 2008 (3 years 7 months) United StatesCorporate Strategy & Business Development + Biomarker / Molecular Dx Tools (IVD) Licensing Leader @ Having successfully conducted commercial & strategy development at the genomics focused CMS business unit of Moto Life Sciences (see slides - below left & right), I specifically:
♦ Secured commercial IP rights for the eSensor molecular diagnostics platform & genetic content (DNA sequences & other biomarkers) for select IVD panels (see chart - below right - for the specific Dx tests)
♦ Led strategic mDx product roadmapping & technology/market gap analysis to assess ‘build-vs.-buy’ opportunities by linking the genomics technology/IP to product functionality driven by customer’s value proposition & demand as determined by my competitive business intelligence & market research. Also see a description of my strategic roadmapping activities in the Project sect. below. Examples of my biotools roadmapping & gap analyses are provided for other I2C projects - further below.
♦ Negotiated genomic biomarker royalty reductions up to 95% enabling multi-million-dollar cost savings by employing profitability analysis & my weighted-contribution (not rule of thumb) royalty structure;
See the materials (a PPT 'handout' & text document) - below left & center that highlight my proven 'road-tested' biotools licensing concepts as well as further written description in the Projects section.
Also see www.AlanKHauser.com From May 2002 to August 2004 (2 years 4 months) Pasadena, CA & Chicagoland, ILStrategic Corporate Business & New Market Development + Omic Biotools Licensing Leader @ Having successfully conducted strategy & commercial development for the genomics powered CodeLink business unit of Moto Life Sciences (see slide below left), I:
● Identified, assessed new genomic opportunities & executed biotools licenses in support of the product launch of CodeLink gene expression & SNP genotyping microarray platforms with integrated system solutions;
● Carried out technical, IP & business due diligence for a major diagnostics acquisition (see slides on right below) as well as other strategic business development (SBD) activities (see diagrams below);
● Created, developed & implemented biotools market development initiative for Massively-Parallel, Multi-Plexed Genomics (MPGx) commercial offering (see roadmapping slides below left & center for details);
● Received Moto BRAVO! Leadership Award for championing the non-array genomics enabled MPGx biotools program;
● Directed commercial aspects of MLS' exploratory proteomics microarray initiative;
● Conducted biotech business, market & intellectual property (IP) due-diligence for Motorola Ventures.
Also see www.AlanKHauser.com From September 1999 to May 2002 (2 years 9 months) Greater Chicago AreaIntellectual Property (IP) Management, Biotools Innovation Commercialization & Licensing Director @ As highlighted in the slide to the left below, I was responsible for the following genomics driven biotools intellectual property (IP) related commercial development & landscaping activities, including licensing & managing ACLARA's organic patent growth:
■ Managed & built broad biotools IP portfolio (comprising of innovative microfluidics-powered genomics discovery research & high throughput screening - HTS - platforms, integrated system solutions, bioinformatics, analytics, diagnostic devices + reagents) from ~10 U.S. patents & applications to more than 130 pending & issued U.S. patents plus hundreds worldwide enabling $189 M IPO
■ Co-invented microfluidic methods for drug screening/genetic analyses that resulted in 4 U.S. patents & more than a dozen pending applications/foreign equivalents (see slide below to the right)
■ Developed & employed preliminary freedom-to-operate & strategic market landscaping tools for visualizing & analyzing competitive technology-IP (TIP) space & new bioscience product offerings
■ Prepared & presented genomic biotools TIP marketing materials that helped lead to 3 major corporate partnerships & significant financing by way of a private placement & eventually a successful IPO.
Also see www.AlanKHauser.com From March 1997 to September 1999 (2 years 7 months) Silicon Valley, CANew Market / Business Development, Strategic Alliances + Biotech Licensing Director @ As pictorially provided in the slide to the left below, I led the following genomics powered biotools corporate strategic business / market development (SBD) and marketing activities at Pangene:
✪ Consummated licenses to innovative DNA recombination methods & novel compositions of matter having broad commercial biotechnology applications, including transgenesis (for both transgenic plants & animals), human therapeutic treatments (gene therapy & vaccines) & molecular diagnostics (testing devices, reagents & informatics/analytics tools)
✪ Forged cancer vaccine strategic alliance & secured biotechnology intellectual property (IP) for in vivo tumor cell immunity methods & compositions of matter
✪ Refocused biotechnology business plan & spearheaded strategic marketing efforts leading to first corporate business to business (B2B) partnership, including co-development discovery research collaboration & exclusive licensing agreements.
As illustrated on the slide below right, my strategic commercial development & marketing efforts were significantly facilitated by an invaluable biotechnology IP attorney & Silicon Valley business executive, Dr. Bertram Rowland. Bert worked closely to coach & mentor me along the exciting professional path from the R&D bench to bioscience new market, strategy & corporate business development via patent law & biotech licensing.
Also see www.AlanKHauser.com From 1995 to 1997 (2 years) Silicon Valley, CATechnological Innovation Assessment & Strategic Market / Commercial Evaluation Leader @ Serving in a full-time technology & market assessment 'consultant' role at SRI, I 'wore many hats' by carrying out I2C technical R&D bench work as well as more commercial functions at the large diversified not-for-profit Silicon Valley CRO:
✔ Evaluated commercial potential of emerging biotechnologies for Business Intelligence Center;
✔ Conducted & managed client-funded feasibility investigations in Science & Technology Group.
In addition, as provided below to the right, I proactively worked in parallel to my responsibilities by day at SRI to ready myself for a future strategic business development (SBD) position at a Silicon Valley biotechnology company and/or new biotools venture by taking IP law & business classes as well as attending licensing & tech transfer conferences & workshops. Subsequently, I was richly rewarded for my extracurricular activities by being most fortunate to have met a game-changing professional mentor at one of my out-of-town technical-business-IP networking events.
Also see www.AlanKHauser.com From 1992 to 1995 (3 years) Silicon Valley, CAPostdoctoral Research Fellow, Hawaii Biosensor Laboratory @ Having developed miniaturized biomolecular recognition sensors & assays for pharmaceutical drug discovery & development as a postdoc at UH, I also learned the following most important Innovation to Commercialization market research lesson as summarized in the slides below by proactively reaching out to biopharma & biotech industry experts & networking to learn more about unmet pharma market needs & other technical life science corporate challenges/hurdles. By doing so, the biotools NIH grant proposal that I was asked by my PI to co-write with another postdoc was eventually funded. From 1990 to 1992 (2 years) Department of ChemistryPostdoctoral Research Fellow @ Leveraging my electroanalytical technical expertise & my passion for converging bioscience with miniaturized electronic innovation that was picked up in grad school, I pursued postdoc research directed toward characterizing & optimizing micro-fabricated biocatalytic sensors, which employed electrochemical-mediated (or 'wired' bioelectronic) detection. I also learned a lesson about the timing for Innovation to Commercialization of medical diagnostics & other biotools at UT as summarized in the slides below. From 1989 to 1990 (1 year) Departments of Chem Engineering, Chem & BiochemDr. Alan K. Hauser's Bioscience Business Biography @ With broad multidisciplinary experience encompassing the technical, IP, market & economic aspects of fostering innovation, Dr. Hauser is a recognized life sciences commercialization leader, CLP & genomics biotools inventor.
Since obtaining his doctorate in chemical & biomolecular engineering from the college of chemistry at U.C. Berkeley, Alan has completed the executive business program at Northwestern's Kellogg Management Institute & finance/valuation courses @ the Univ. of Chicago & Harvard business schools.
Alan has been building businesses for 15+ years based on disruptive biotechnologies that are transforming the medical practice. His corporate development, strategic roadmapping & licensing efforts have led to the market introduction of an FDA-cleared DNA detection system that is enabling emerging pharmacogenomics driven diagnosis & treatments. Alan built a robust microfluidics patent portfolio for a venture-backed Si Valley biotools startup that resulted in its $189 MM IPO. Dr. Hauser also facilitated the assessment of 50+ NU I2C opportunities while coaching/mentoring 40 INVO interns.
Alan's experience (see summary-below left) includes 2 postdoctoral research fellowships, a proven commercial development track record of demonstrated intra-entrepreneurship at a large CRO (SRI International), 2 Bay Area genomics based biotech startups (Pangene Corp. & ACLARA BioSciences), a Fortune 100 Co (Moto Life Sciences CodeLink & Clinical Micro Sensors - eSensor - businesses) & as a strategic management consultant at Bio-Com & CDx Health Economics. Having also directed the technology licensing team & served as executive director of strategic business development at NU's Innovation & New Ventures Office (fka Tech Transfer Program), Dr. Hauser is currently continuing to catalyze biotech innovation to commercialization (Bio•I2C) via strategic business development, roadmapping, new product planning, emerging market research & economic analysis. Also see www.AlanKHauser.com From 1989 to 1989 (less than a year)
Northwestern's Kellogg Mgmt Institute (KMI) Executive Program, Business Administration & Leadership @ Kellogg School of Management Executive Business Program; PhD Chemical & Biomolecular Engineering, UC Berkeley From 2001 to 2002 PhD, Chemical & Biomolecular Engineering, College of Chemistry @ University of California, Berkeley From 1984 to 1989 Executive Finance Programs, Valuation & Corporate Venture Capital @ Harvard Business SchoolMBA Courses:, Tech. Strategy, Corporate Finance, Private Equity & Entrepreneurial Finance @ The University of Chicago Booth School of Business Alan Hauser is skilled in: Commercialization, Business Development, Licensing, Strategic Planning, Life Sciences, Drug Discovery, Genomics, Molecular Diagnostics, Oncology, Corporate Development, Biomarkers, Personalized Medicine, Due Diligence, Business Planning, Medical Diagnostics, Intellectual Property, Market Development, Valuation, M&A experience, Lifesciences, Pharmacogenomics, Project Management, Competitive Landscape..., Patents, Technology..., Start-ups, Business Intelligence, Technology/Market Gap..., Nucleic Acid Sample Prep, Commercial development, Technology Transfer, Companion Diagnostics, Microarrays, Clinical Diagnostics, Venture Capital, Genomic Tools, Product Roadmapping, Roadmap, Biotechnology, Strategic M&A, Innovation, Microfluidics, Bioscience, Business Modeling, Biomedical Devices, Entrepreneurship, Customer Development, New Venture Creation, Contract Negotiations, Tech & Market...